

Table S4. Clinical and laboratory characteristics of patients with and without renal dysfunction (in patients with left atrial thrombus, derivation cohort).

Variable	Patients with LAA thrombus (n=59)		p
	Patients with renal dysfunction (GFR <56 mL/min/1.73m ²) (n=30)	Patients without renal dysfunction (GFR ≥56 mL/min/1.73m ²) (n=29)	
Age [years]	69 (61-78)	63 (58-71)	0.06
Female [n (%)]	11 (37%)	10 (34%)	1.00
BMI [kg/m ²]	28 (24-31) <i>n=17</i>	31 (27-34) <i>n=20</i>	0.06
Type of atrial fibrillation (AF) [n (%)]			
Paroxysmal AF	5 (17%)	5 (17%)	1.00
Persistent AF	18 (60%)	18 (62%)	1.00
Permanent AF	7 (23%)	6 (21%)	1.00
Type of procedure planned [n (%)]			
Cardioversion	4 (13%)	4 (14%)	1.00
Ablation	26 (87%)	25 (86%)	1.00
Concomitant diseases [n (%)]			
Hypertension	17 (57%)	21 (72%)	0.28
Dyslipidemia	7 (23%)	11 (38%)	0.27
Diabetes	10 (33%)	8 (28%)	0.78
Coronary artery disease	7 (23%)	7 (24%)	1.00
Previous myocardial infarction	4 (13%)	5 (17%)	0.73
Peripheral artery disease	1 (3.3%)	0 (0%)	1.00

Vascular disease (CAD and/or PAD)	7 (23%)	7 (24%)	1.00
Heart failure	15 (50%)	9 (31%)	0.19
Previous ischemic stroke/ TIA/embolism	6 (20%)	3 (10%)	0.47
Previous peripheral embolism	0 (0%)	2 (7.1%)	0.23
Previous hemorrhagic stroke	0 (0%)	0 (0%)	1.00
Biological valve prosthesis	2 (6.7%)	0 (0%)	0.49
Mechanical valve prosthesis	0 (0%)	1 (3.5%)	0.49
Chronic respiratory disease	3 (10%)	4 (14%)	0.71
Liver disease	0 (0%)	1 (3.5%)	0.49
Hyperthyroidism	4 (13%)	2 (6.9%)	0.67
Hypothyroidism	4 (13%)	0 (0%)	0.11
Malignancy	1 (3.3%)	3 (10%)	0.35
Hyperuricemia	2 (6.7%)	0 (0%)	0.49
Smoking	9 (30%)	10 (34%)	1.00
Thromboembolic risk			
CHADS ₂ score	3 (2-4)	3 (2-3)	0.24
CHA ₂ DS ₂ -VASc score	3 (1-4)	2 (2-3)	0.25
CHA ₂ DS ₂ -VASc score [n (%)]			
= 0	0 (0%)	1 (4%)	0.53
= 1	8 (27%)	5 (17%)	0.53
≥ 2	22 (73%)	23 (79%)	0.53
Antithrombotic treatment [n (%)]			
No OAC	3 (10%)	3 (10%)	1.00
VKA	13 (43%)	17 (59%)	0.30
NOAC	14 (47%)	9 (31%)	0.29

- dabigatran	10 (33%)	3 (10%)	0.06
- rivaroxaban	4 (14%)	6 (21%)	0.73
- apixaban	0 (0%)	0 (0%)	1.00
Antiplatelets	2 (6.7%)	0 (0%)	0.49
Laboratory parameters			
Hemoglobin [g/dL]	14 (13-15)	14 (13-16)	0.24
WBC [K/ μ L]	7.6 (6.8-9.4)	7.1 (6.1-8.9)	0.18
Platelet count [K/ μ L]	187 (142-237)	209 (170-286)	0.21
GFR [mL/min/1.73 m ²]	47 (39-54)	81 (70-89)	<.0001
Transthoracic echocardiography*			
Ejection fraction [%]	52 (50-55) <i>n=5</i>	57 (49-64) <i>n=6</i>	0.41
Left atrial diameter [cm]	4.4 (4.1-4.7) <i>n=6</i>	5.1 (4.7-5.4) <i>n=8</i>	0.03
Transesophageal echocardiography*			
LAA emptying velocity [cm/s]	24 (20-29)	21 (18-27)	0.36
Dense SEC [n (%)]	12 (40%)	5 (17%)	0.08
SEC [n (%)]	13 (43%)	17 (59%)	0.30

* performed during index hospitalization

AF - atrial fibrillation, BMI - body mass index, CAD - coronary artery disease, GFR – glomerular filtration rate, LAA – left atrial appendage, NOAC - non-vitamin K antagonist oral anticoagulants, PAD - peripheral artery disease, SEC - spontaneous echo contrast, TIA - transient ischemic attack, VKA - vitamin K antagonists, WBC - white blood cells